Betnovate 0.1% scalp application Lielbritānija - angļu - MHRA (Medicines & Healthcare Products Regulatory Agency)

betnovate 0.1% scalp application

glaxosmithkline uk ltd - betamethasone valerate - cutaneous liquid - 1mg/1gram

Betnovate 0.1% ointment Lielbritānija - angļu - MHRA (Medicines & Healthcare Products Regulatory Agency)

betnovate 0.1% ointment

glaxosmithkline uk ltd - betamethasone valerate - cutaneous ointment - 1mg/1gram

Betnovate 0.1% lotion Lielbritānija - angļu - MHRA (Medicines & Healthcare Products Regulatory Agency)

betnovate 0.1% lotion

glaxosmithkline uk ltd - betamethasone valerate - cutaneous liquid - 1mg/1gram

Synovial fluid supplementation substance Austrālija - angļu - Department of Health (Therapeutic Goods Administration)

synovial fluid supplementation substance

lmt surgical pty ltd - 44757 - synovial fluid supplementation substance - intended to be used for intra-articular injection for symptomatic treatment of knee osteoarthritis.

BETNOVATE CREAM 0.1% Malaizija - angļu - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

betnovate cream 0.1%

glaxosmithkline pharmaceutical sdn. bhd. - betamethasone -

Betnovate Ointment 0.1% w/w Malta - angļu - Medicines Authority

betnovate ointment 0.1% w/w

glaxo smithkline ireland limited 12, riverwalk, citywest business campus, dublin 24, ireland - betamethasone valerate - ointment - betamethasone valerate 0.1 % (w/w) - corticosteroids, dermatological preparations

Betnovate Cream 0.1% w/w Malta - angļu - Medicines Authority

betnovate cream 0.1% w/w

glaxo smithkline ireland limited 12, riverwalk, citywest business campus, dublin 24, ireland - betamethasone valerate - cream - betamethasone valerate 0.1 % (w/w) - corticosteroids, dermatological preparations

BETNOVATE RD CREAM 0.025% w/w Singapūra - angļu - HSA (Health Sciences Authority)

betnovate rd cream 0.025% w/w

glaxosmithkline pte ltd - betamethasone valerate eqv betamethasone - cream - 0.025% w/w

Euflexxa 1% sodium hyaluronate - Synovial fluid supplementation substance Austrālija - angļu - Department of Health (Therapeutic Goods Administration)

euflexxa 1% sodium hyaluronate - synovial fluid supplementation substance

ferring pharmaceuticals pty ltd - 44757 - synovial fluid supplementation substance - a very highly purified viscoelastic, sterile solution of highly purified, high molecular weight (2.4-3.6 million daltons) hyaluronan (also known as sodium hyaluronate) in phosphate-buffered saline; extracted from bacterial cells. a polysaccharide consisting of a repeating disaccharide of n-acetylglucosamine and sodium glucuronate, linked by alternating b? 1,3 and b? 1,4 glycosidic bonds. euflexxa is indicated for the treatment of pain caused by osteoarthritis of the knee joint or other synovial joints. euflexxa aids in lubrication of the joint, allows for greater mobility and flexibility of the treated joint, and reduces pain in the affected joint.

MONOVISC? Cross linked Sodium Hyaluronate - Synovial fluid supplementation substance Austrālija - angļu - Department of Health (Therapeutic Goods Administration)

monovisc? cross linked sodium hyaluronate - synovial fluid supplementation substance

surgical specialties pty ltd - 44757 - synovial fluid supplementation substance - monovisc? cross-linked sodium hyaluronate injection is a single, intra-articular injection of cross-linked sodium hyaluronate designed to treat the symptoms of osteoarthritis. the actions of monovisc? are lubrication and mechanical support. monovisc is indicated as a viscoelastic supplement or a replacement for synovial fluid in human knee joints. monovisc is well suited for treatment of the symptoms of mild to moderate osteoarthritis of the human knee joints for patients who have failed to respond adequately to conservative non-pharmacologic therapy and simple analgesics.